Back to top
more

DaVita (DVA)

(Real Time Quote from BATS)

$139.56 USD

139.56
174,052

-1.37 (-0.97%)

Updated May 21, 2024 01:06 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.08%
2Buy17.91%
3Hold9.44%
4Sell5.10%
5Strong Sell2.55%
S&P50011.04%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 19% (48 out of 248)

Industry: Medical - Outpatient and Home Healthcare

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Founded in 1994 and headquartered in Denver, CO, DaVita Inc. is a leading provider of dialysis services in the U.S. to patients suffering from chronic kidney failure, also known as end stage renal disease (ESRD). The company operates kidney dialysis centers and provides related medical services primarily in dialysis centers and in contracted hospitals across the U.S. Its services include outpatient dialysis services, hospital inpatient dialysis services and ancillary services such as ESRD laboratory services and disease management services.

DaVita (DVA) Gains 34.5% YTD: What's Driving the Stock?

by Zacks Equity Research

DaVita's (DVA) shares gain on the back of strong fundamentals. However, dependence on commercial payers can be a cause of concern.

Three Reasons to Retain Inspire Medical (INSP) Stock for Now

by Zacks Equity Research

Inspire Medical's (INSP) focus on R&D raises optimism about the stock.

McKesson (MCK) Hits 52-Week High: What's Driving the Stock?

by Zacks Equity Research

Investors are optimistic about McKesson's (MCK) strength in its Biologics business.

Masimo's (MASI) New Offering to Serve Personalized Audio Market

by Zacks Equity Research

Masimo's (MASI) new product offering is expected to enable it to expand its footprint in the personalized hearables market by offering personalized listening experiences.

Boston Scientific (BSX) Reaches 52-Week High: What's Aiding It?

by Zacks Equity Research

Investors are optimistic about Boston Scientific's (BSX) impressive market share gain in the MedSurg segment and continued geographical expansion.

Here's Why You Should Hold Surmodics (SRDX) Stock for Now

by Zacks Equity Research

Surmodics' (SRDX) solid prospects in the thrombectomy business raise optimism about the stock.

BD's (BDX) FDA-Approved Test to Offer Wider Testing Access

by Zacks Equity Research

BD's (BDX) receipt of the FDA's clearance for the use of self-collected vaginal specimens for HPV testing is likely to improve screening access to a wider female population.

Reasons to Retain DexCom (DXCM) Stock in Your Portfolio Now

by Zacks Equity Research

DexCom (DXCM) continues to raise optimism among investors, owing to its strong product portfolio.

Butterfly Network (BFLY) Unveils iQ+ Bladder Ultrasound Scanner

by Zacks Equity Research

Butterfly Network (BFLY) uses proprietary Ultrasound-on-Chip technology to streamline the bladder scanning process.

Three Reasons to Retain AMN Healthcare (AMN) Stock for Now

by Zacks Equity Research

Investors remain optimistic about AMN Healthcare's (AMN) broad array of services.

Profound Medical (PROF) Adds AI to Prostate Cancer Treatment

by Zacks Equity Research

Profound Medical's (PROF) Contouring Assistant integrates AI into prostate cancer procedures, thereby streamlining the treatment planning process and enhancing both efficiency and precision.

Centene (CNC) to Continue Serving Kansas' Medicaid Members

by Zacks Equity Research

Centene's (CNC) subsidiary wins contract from the Kansas Department of Administration to continue providing comprehensive healthcare services to the KanCare program's members.

Merit Medical (MMSI) to Expand Product Suite Via New Launch

by Zacks Equity Research

Merit Medical's (MMSI) latest additions to its embolotherapy portfolio are likely to improve the patient experience.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Senseonics' (SENS) Deal With Mercy to Drive Eversense CGM Sales

by Zacks Equity Research

Senseonics Holdings (SENS) collaborates with Mercy to bring its Eversense CGM to a healthcare system that is likely to drive its adoption.

Stereotaxis (STXS) Inks Deal to Buy Access Point Technologies

by Zacks Equity Research

Stereotaxis' (STXS) deal to acquire electrophysiology catheter developer, Access Point Technologies, is likely to strengthen its position within the catheter market.

Baxter's (BAX) Clinolipid Gets FDA's Expanded Indication

by Zacks Equity Research

Baxter's (BAX) receipt of the latest expanded indication for Clinolipid is expected to meet the diverse nutritional needs of patients, ranging from preterm neonates to adults.

Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?

by Zacks Equity Research

Investors are optimistic about Glaukos' (GKOS) strength in its flagship iStent.

Reasons to Add The Cooper Companies (COO) to Your Portfolio

by Zacks Equity Research

The Cooper Companies (COO) benefits from strength in its business segments. Its acquisitions are likely to drive the top line. A rise in selling, general and administrative expenses is, however, concerning.

Three Reasons to Retain Integer Holdings (ITGR) Stock for Now

by Zacks Equity Research

Integer Holdings' (ITGR) research and product development activities raise optimism about the stock.

Catalent's (CTLT) Latest Partnership to Boost Clinical Trials

by Zacks Equity Research

Catalent's (CTLT) new tie-up to support the development and commercial manufacturing of safe, high-quality AAV gene therapies to provide life-saving treatments to cancer patients.

Encompass Health Corporation (EHC) Hits Fresh High: Is There Still Room to Run?

by Zacks Equity Research

Encompass Health (EHC) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Zacks.com featured highlights Hasbro, Brinker International, DaVita, Leidos Holdings and Allstate

by Zacks Equity Research

Hasbro, Brinker International, DaVita, Leidos Holdings and Allstate have been highlighted in this Screen of The Week article.

Vasundhara Sawalka headshot

5 Stocks Trading Near 52-Week High With More Upside Potential

by Vasundhara Sawalka

Investors target stocks that have lately been on a bull run. Stocks like HAS, EAT, DVA, LDOS and ALL are seeing price strength and have a high chance of carrying the momentum forward.

Tirthankar Chakraborty headshot

4 Must-Buy Momentum Stocks Banking on the Driehaus Strategy

by Tirthankar Chakraborty

DaVita (DVA), Minerals Technologies (MTX), Alphabet (GOOGL) and Garmin (GRMN) have been selected as the momentum picks for the day using the Driehaus strategy.